Kotak Mahindra Bank ADD

Management rejig to hopefully arrest top management attrition

BFSI - Banks > Company Update > February 19, 2024

Kotak Mahindra Bank (KMB) has undertaken a major top-management rejig (w.e.f 01-Mar-24), mainly elevating KVS Manian as JMD (replacing ex-JMD Dipak Gupta) and Shanti Ekambaram as DMD (possibly a notch below the JMD), Dipak Gupta) and Shanti Ekambaram as DMD (possibly a notch below the JMD), subject to RBI approval. Notably, there was news-flow suggesting that Mr Manian could be one of the candidates for the MD & CEO post (due to be vacated in Sep-24) at Federal Bank, but KMB's move should potentially eliminate any such risk. Separately, retiring group CFO Jaimin Bhatt will be replaced by Deepak Gheewala (COO), while Milind Nagnur will now hold the dual position of CTO & COO. Paul Parambi (CRO - KMB) has been elevated as Group CRO. We believe such a rejig by KMB should possibly alleviate any immediate risk of top management attrition, but the new MD will still have the task of curbing attrition at the operational level, manage the ensuing asset quality risk, and hopefully review Bank's strategic stance on business/branch expansion, investment portfolio rejig given higher share of AFS, sub-optimal dividend/capital consumption policy, stake reduction in subs, etc. We retain ADD and Rs1,950 TP, implying 2.5x Dec-25E core Bank ABV+Rs480 subs value.

Y23 FY24E	FY25E	FY26E
202 120 665		
393 128,665	142,001	155,187
17.9 16.1	16.0	17.9
28.1 19.2	12.0	14.6
4.9 5.1	4.9	4.8
23.2 26.6	13.1	15.4
5.1 64.8	71.4	78.1
27.5 17.5	10.3	9.3
97.5 458.1	524.4	596.3
.6.1 15.0	14.0	13.3
2.4 2.4	2.3	2.2
4.1 14.4	13.8	13.2
22.7 19.3	17.5	16.0
3.1 2.7	2.4	2.1
	17.9 16.1 28.1 19.2 4.9 5.1 23.2 26.6 55.1 64.8 27.5 17.5 97.5 458.1 16.1 15.0 2.4 2.4 14.1 14.4 22.7 19.3	17.916.116.028.119.212.04.95.14.923.226.613.155.164.871.427.517.510.397.5458.1524.416.115.014.02.42.42.314.114.413.822.719.317.5

Source: Company, Emkay Research



Ticker

TARGET PRICE (Rs): 1,950

Target Price – 12M	Dec-24
Change in TP (%)	NA
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	12.6
CMP (19-Feb-24) (Rs)	1,731.4

Stock Data

otoen butu	menter
52-week High (Rs)	2,064
52-week Low (Rs)	1,644
Shares outstanding (mn)	1,987.9
Market-cap (Rs bn)	3,442
Market-cap (USD mn)	41,460
Net-debt, FY24E (Rs mn)	NA
ADTV-3M (mn shares)	4
ADTV-3M (Rs mn)	8,012.3
ADTV-3M (USD mn)	96.5
Free float (%)	74.0
Nifty-50	22,122
INR/USD	83.0
Shareholding, Dec-23	
Promoters (%)	25.9
FPIs/MFs (%)	38.1/23.1

Price Perform	ance		
(%)	1M	3M	12M
Absolute	(1.9)	(1.9)	(1.6)
Rel. to Nifty	(4.1)	(12.5)	(20.2)



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275

Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/24/2024 12:27 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions Refer to Important Disclosures at the end of this report on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Kotak Mahindra Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	270,388	342,509	457,521	507,602	568,476
Interest Expense	102,209	126,989	200,582	219,830	238,689
Net interest income	168,179	215,519	256,939	287,772	329,788
NII growth (%)	9.6	28.1	19.2	12.0	14.6
Other income	59,859	70,830	97,238	116,247	137,370
Total Income	228,038	286,350	354,177	404,019	467,158
Operating expenses	107,530	137,870	166,254	191,455	221,850
РРОР	120,509	148,480	187,923	212,565	245,308
PPOP growth (%)	2.5	23.2	26.6	13.1	15.4
Core PPOP	114,896	120,518	156,037	185,656	208,484
Provisions & contingencies	6,896	4,570	17,054	22,977	38,115
РВТ	113,613	143,910	170,869	189,587	207,192
Extraordinary items	0	0	0	0	(
Tax expense	27,886	34,517	42,205	47,586	52,005
Minority interest	0	0	0	0	(
Income from JV/Associates	0	0	0	0	C
Reported PAT	85,727	109,393	128,665	142,001	155,187
PAT growth (%)	23.1	27.6	17.6	10.4	9.3
Adjusted PAT	85,727	109,393	128,665	142,001	155,187
Diluted EPS (Rs)	43.0	55.1	64.7	71.4	78.1
Diluted EPS growth (%)	22.4	28.0	17.5	10.3	9.3
DPS (Rs)	1.1	1.5	2.0	2.5	3.0
Dividend payout (%)	2.6	2.5	2.7	3.1	3.5
Effective tax rate (%)	24.5	24.0	24.7	25.1	25.1
Net interest margins (%)	4.3	4.9	5.1	4.9	4.8
Cost-income ratio (%)	47.2	48.1	46.9	47.4	47.5
Shares outstanding (mn)	1,984.7	1,986.6	1,987.6	1,987.6	1,987.6

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	9,923	9,933	9,938	9,938	9,938
Reserves & surplus	709,955	820,270	949,958	1,086,953	1,236,114
Net worth	719,878	830,203	959,896	1,096,891	1,246,052
Deposits	3,116,841	3,630,961	4,296,509	5,016,282	5,961,004
Borrowings	259,671	234,163	274,124	302,436	333,480
Interest bearing liab.	3,376,512	3,865,123	4,570,633	5,318,718	6,294,484
Other liabilities & prov.	197,894	203,299	104,227	132,751	188,566
Total liabilities & equity	4,294,284	4,898,625	5,634,756	6,548,361	7,729,103
Net advances	2,712,536	3,198,612	3,712,225	4,306,531	5,079,12
Investments	1,005,802	1,214,037	1,436,533	1,673,593	1,988,894
Cash, other balances	429,239	325,423	310,803	372,310	440,614
Interest earning assets	3,683,959	4,147,578	4,738,072	5,459,561	6,352,434
Fixed assets	16,437	19,203	19,700	22,274	25,210
Other assets	130,269	141,349	155,495	173,653	195,253
Total assets	4,294,284	4,898,625	5,634,756	6,548,361	7,729,103
BVPS (Rs)	363.0	418.1	480.6	549.4	624.4
Adj. BVPS (INR)	341.3	397.5	458.1	524.4	596.3
Gross advances	2,759,866	3,244,362	3,763,460	4,365,614	5,151,424
Credit to deposit (%)	87.0	88.1	86.4	85.9	85.2
CASA ratio (%)	60.7	52.8	47.8	47.2	48.
Cost of deposits (%)	3.1	3.5	4.7	4.4	4.
Loans-to-Assets (%)	63.2	65.3	65.9	65.8	65.3
Net advances growth (%)	21.3	17.9	16.1	16.0	17.9
Deposit growth (%)	11.3	16.5	18.3	16.8	18.8
Book value growth (%)	11.8	15.2	14.9	14.3	13.3

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key	Ratios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	28.9	22.7	19.3	17.5	16.0
P/B (x)	3.6	3.1	2.7	2.4	2.1
P/ABV (x)	3.7	3.1	2.7	2.4	2.1
P/PPOP (x)	28.5	23.2	18.3	16.2	14.0
Dividend yield (%)	0.1	0.1	0.1	0.1	0.2
DuPont-RoE split (%)					
NII/avg assets	4.1	4.7	4.9	4.7	4.6
Other income	1.5	1.5	1.8	1.9	1.9
Fee income	1.3	1.6	1.7	1.7	1.8
Opex	2.6	3.0	3.2	3.1	3.1
PPOP	3.0	3.2	3.6	3.5	3.4
Core PPOP	3.1	3.0	3.4	3.5	3.4
Provisions	0.2	0.1	0.3	0.4	0.5
Tax expense	0.7	0.8	0.8	0.8	0.7
RoA (%)	2.1	2.4	2.4	2.3	2.2
Leverage ratio (x)	6.0	5.9	5.9	6.0	6.1
RoE (%)	12.7	14.1	14.4	13.9	13.3
Quarterly data					
Rs mn, Y/E Mar	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24
NII	56,529	61,026	62,337	62,966	65,535
NIM (%)	5.5	5.8	5.6	5.2	5.2
PPOP	38,498	46,474	49,496	46,101	45,662
PAT	27,919	34,956	34,523	31,910	30,050
EPS (Rs)	14.06	17.60	17.38	16.06	15.13

4.4

Source: Company, Emkay Research

Source: Company, Emkay Research

Y/E Mar (Rs mn)

Asset quality

GNPA ratio (%)

NNPA ratio (%)

Gross slippages

LLP ratio (%)

Tier-1 (%)

CET-1 (%)

Miscellaneous Total income growth (%)

Opex growth (%)

PPOP margin (%)

Cost of funds (%)

PAT/PPOP (%)

Core PPOP growth (%)

LLP-to-Core PPOP (%)

Yield on advances (%)

Provision coverage (%)

Gross slippage ratio (%)

NNPA to networth (%)

RWA-to-Total Assets (%)

Capital adequacy Total CAR (%)

Gross NPLs

Net NPLs

Asset quality and other metrics

FY22

64.697.4

17,367.1

2.3

0.6

73.2

1.3

0.3

2.4

23.7

21.7

21.5

77.7

3.7

25.3

4.9

36.5

71.1

6.0

7.9

3.2

17,971.3

FY23

57.683.2

11,933.0

1.8

0.4

79.3

1.1

0.2

1.4

21.8

20.6

19.0

76.0

25.2

28.2

29.5

35.9

73.7

3.8

9.2

3.5

18,582.1

FY24E

64.043.4

12,808.7

1.7

0.3

80.0

1.0

0.4

1.3

21.3

20.3

18.9

78.0

34.2

20.6

19.0

33.9

68.5

10.9

10.4

4.8

19,952.4

FY25E

19,694.3

1.8

0.5

75.0

1.5

0.6

1.8

21.1

20.1

19.0

78.0

12.5

15.2

12.3

34.1

66.8

12.4

10.0

33,949.7

78,777,4 100,413,4

FY26E

28,115.7

1.9

0.6

72.0

2.4

0.8

2.2

20.3

19.5

18.5

78.0

13.1

15.9

15.6

34.8

63.3

18.3

9.6

4.1

54,883.0

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/24/2024 12:27 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
21-Jan-24	1,807	1,950	Add	Anand Dama
30-Nov-23	1,755	1,955	Add	Anand Dama
22-Oct-23	1,770	1,955	Hold	Anand Dama
23-Jul-23	1,969	2,000	Hold	Anand Dama
30-Apr-23	1,936	2,000	Hold	Anand Dama
09-Mar-23	1,715	2,000	Hold	Anand Dama
22-Jan-23	1,761	2,000	Hold	Anand Dama
24-Oct-22	1,894	2,230	Buy	Anand Dama
06-Sep-22	1,914	2,230	Buy	Anand Dama
23-Jul-22	1,825	2,180	Buy	Anand Dama
26-May-22	1,906	2,180	Buy	Anand Dama
05-May-22	1,795	2,180	Buy	Anand Dama
29-Jan-22	1,896	2,300	Buy	Anand Dama
27-Oct-21	2,185	2,350	Hold	Anand Dama
27-Jul-21	1,695	2,000	Hold	Anand Dama
03-May-21	1,722	2,000	Hold	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/24/2024 12:27 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/24/2024 12:27 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of February 19, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of February 19, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the February 19, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/24/2024 12:27 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.